Navidea Biopharmaceuticals (NAVB) Competitors

TC Biopharm (NASDAQ:TCBP) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.

Which has higher valuation & earnings, TCBP or NAVB?

TC Biopharm has higher revenue and earnings than Navidea Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76M	0.06	-$7.35M	N/A	N/A
Navidea Biopharmaceuticals	$8.13K	8.62	-$15.18M	N/A	N/A

Do insiders and institutionals have more ownership in TCBP or NAVB?

16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts prefer TCBP or NAVB?

TC Biopharm currently has a consensus target price of $48.00, suggesting a potential upside of 6,948.46%. Given TC Biopharm's stronger consensus rating and higher probable upside, analysts plainly believe TC Biopharm is more favorable than Navidea Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Navidea Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is TCBP or NAVB more profitable?

Company	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Does the media favor TCBP or NAVB?

In the previous week, TC Biopharm had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for TC Biopharm and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 beat TC Biopharm's score of -0.36 indicating that Navidea Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
TC Biopharm	Neutral
Navidea Biopharmaceuticals	Neutral

Does the MarketBeat Community believe in TCBP or NAVB?

TC Biopharm received 2 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 66.67% of users gave TC Biopharm an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote.

Company	Underperform	Outperform
TC Biopharm	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%
Navidea Biopharmaceuticals	Outperform Votes No Votes	Underperform Votes 87 100.00%

Which has more risk and volatility, TCBP or NAVB?

TC Biopharm has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.

Summary

TC Biopharm beats Navidea Biopharmaceuticals on 9 of the 13 factors compared between the two stocks.